Overall, analysts tracked by FactSet expect UnitedHealth to post $101.6 billion in revenue, up from $94.4 billion a year prior. Analysts also model $6.73 in adjusted earnings per share, up from $6.16 ...
A new report by the Federal Trade Commission says pharmacy benefit management companies are driving up your out-of-pocket costs for prescription drugs.
The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs by $7.3 billion over six years.
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...
A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer and HIV treatments between 2017-2022.
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
The markups helped the PBMs reap $7.3 billion from 2017 to 2022, the FTC found. The PBMs—owned by insurers Cigna, CVS Health and UnitedHealth Group—are supposed to help keep drug costs low for ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback